On Tuesday, Shares of Exelixis, Inc. (NASDAQ:EXEL), gained 2.89% to $6.05, hitting its highest level.
Exelixis, declared that it plans to offer, subject to market and other conditions, 20,000,000 shares of its common stock in an underwritten public offering. The company anticipates to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering will be sold by Exelixis.
Cowen and Company, William Blair and Stifel are acting as bookrunners for the offering. The offering is being conducted by means of a prospectus supplement filed as part of a shelf registration statement formerly filed with the Securities and Exchange Commission (SEC) on Form S-3.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Shares of Bristol-Myers Squibb Company (NYSE:BMY), declined -1.57% to $68.87, during its last trading session.
Bristol-Myers Squibb Company, declared additional Phase IIa proof-of-concept data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1. The study findings, which are being presented in a late-breaking oral presentation at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, confirmed the antiretroviral activity of BMS-955176 when administered with atazanavir (± ritonavir) and support further development of the second-generation HIV-1 maturation inhibitor.
BMS-955176 is designed to inhibit one of the last steps of the HIV-1 viral lifecycle, resulting in the release of immature non-infectious HIV-1 particles. As part of a multi-part proof-of-concept study, a two-drug combination of BMS-955176 (80 mg) plus atazanavir (unboosted) had a maximum median change in HIV-1 RNA of -2.23 log10 c/mL from baseline through study discharge (Day 42). The standard of care (SOC) control of atazanavir 300 mg and ritonavir 100 mg plus tenofovir disoproxyl fumarate 300 mg plus emtricitabine 200 mg in a fixed dose combination had a maximum median change in HIV-1 RNA of -2.39 log10 c/mL from baseline through study discharge (Day 42). In addition, a lower dose of BMS-955176 (40 mg) plus atazanavir and ritonavir had a similar maximum median change in HIV-1 RNA of -2.20 log10 c/mL. Length of therapy for all treatment groups was 28 days. Study endpoints comprised of change in HIV-1 RNA from baseline to Day 28 and from baseline to the end of the study (Day 42) and safety.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, Reliance Steel & Aluminum Co. (NYSE:RS), ended its last trade with -1.09% loss, and closed at $58.06.
Reliance Steel & Aluminum, declared that it will report second quarter financial results for the period ended June 30, 2015, on Thursday, July 23, 2015, at 8:50 a.m. Eastern Time. Reliance administration will host a conference call that same day at 11:00 a.m. Eastern Time.
Reliance Steel & Aluminum Co. operates as a metals service center company. The company provides metals processing services and distributes a line of about 100,000 metal products, counting alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium, and specialty steel products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
